Abstract
Our objective was to examine the brain biopsies by histopathology and investigate the prognosis of patients with myelin oligodendrocyte glycoprotein antibody-associated demyelinating pseudotumor. The clinical, MRI, and histological features of two patients with myelin oligodendrocyte glycoprotein antibody-associated demyelinating pseudotumor were reviewed. Both patients were treated with steroid plus rituximab and followed up. The brain biopsies of both cases revealed T cells, macrophages, and complement-mediated demyelination, which was in accord with multiple sclerosis-like pathology. Moreover, both cases showed favorable response to steroid plus rituximab therapy. Our cases add a new variant to the myelin oligodendrocyte glycoprotein-encephalomyelitis spectrum, which favorably responds to immunotherapy.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Autoantibodies / adverse effects*
-
Demyelinating Diseases / chemically induced*
-
Demyelinating Diseases / diagnosis
-
Demyelinating Diseases / pathology
-
Encephalomyelitis / drug therapy
-
Encephalomyelitis / pathology
-
Humans
-
Immunologic Factors / metabolism
-
Male
-
Middle Aged
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / pathology
-
Myelin-Associated Glycoprotein / metabolism
-
Myelin-Oligodendrocyte Glycoprotein / metabolism*
-
Nervous System Malformations / drug therapy
-
Nervous System Malformations / pathology*
-
Oligodendroglia / drug effects
-
Oligodendroglia / metabolism
Substances
-
Autoantibodies
-
Immunologic Factors
-
Myelin-Associated Glycoprotein
-
Myelin-Oligodendrocyte Glycoprotein
Grants and funding
This work was funded by National Natural Science Foundation of China grants 81771300 and 81701188.